Table 1 Baseline characteristics and ATS/ALAS/JRS diagnostic findings and diagnostic confidence (N = 148)

Age at dx, years (mean SD (range))

65 (11.6)

60 (13.9)

 < 0.0001

Sex, M (%)/F (%)

45 (51)

24 (40)

0.182

Ever smoking history, N (%)

31 (35)

25 (41)

0.429

TLC%, median (IQR 25–75) (N = 105)

69 (60–81)

81 (71–98)

 < 0.0001

FVC%, median (IQR 25–75) (N = 130)

61 (52–76)

76 (66–84)

0.0006

DLCO%, median (IQR 25–75) (N = 118)

45 (37–52)

58 (48–72)

 < 0.0001

Initial treatment, N (%)

 Corticosteroids

 Steroid-sparing agent

 None/observed

66 (75)

8 (9)

14 (16)

50 (83)

1 (2)

8 (13)

0.159

Short-term clinical course (6–12 months), N (%)

0.829

 Improved/stabilized

 Worsened

 Unknown

70 (80)

8 (9)

10 (11)

48 (80)

4 (7)

8 (13)

All-cause mortality, N (%)

40 (45)

8 (13)

 < 0.0001

Exposure hx, N (%)

0.159

 Avian

 Mold/bacterial

 Other

 Multiple

 Documented unknown

23 (26)

15 (17)

8 (9)

4 (5)

38 (43)

8 (30)

15 (25)

9 (15)

4 (7)

14 (23)

Precipitin testing, N (%)

0.391

 Positive avian

 Positive mold/bacterial

 Positive multiple

 Negative

 Not obtained

22 (25)

6 (7)

6 (7)

42 (48)

12 (14)

9 (15)

3 (5)

3 (5)

31 (52)

14 (23)

Individual radiologic* findings

GGO, N (%)

69 (78)

50 (83)

–

Mosaic attenuation, N (%)

58 (65)

36 (60)

–

Centrilobular nodules, N (%)

15 (17)

18 (30)

–

Reticulation/traction bronchiectasis, N (%)

82 (96)

–

–

Honeycombing, N (%)

15 (17)

–

–

Overall CT pattern for HP, ** N (%)

0.477

 Typical

 Compatible

 Indeterminate

52 (59)

22 (25)

14 (16)

32 (53)

10 (17)

18 (30)

Histopathology findings**, (N = 133)

(N = 72)

(N = 58)

0.125

Consistent, N (%)

Probable, N (%)

Indeterminate, N (%)

42 (51)

23 (32)

10 (14)

40 (69)

15 (26)

3 (5)

Overall ATS/JRS/ALAT Diagnostic Confidence Level**

0.844

 Moderate, N (%)

 High, N (%)

 Definite, N (%)

55 (62)

21 (24)

12 (14)

35 (58)

15 (25)

15 (17)